bevacizumab – Medxy AI

U-BOMB Phase 2 Trial: Promising Activity of Utidelone Plus Bevacizumab in ERBB2-Negative Metastatic Breast Cancer with Active Brain Metastases

By MedXY 09/12/2025

The U-BOMB phase 2 trial demonstrates that the combination of utidelone and bevacizumab shows encouraging efficacy and tolerability in patients with ERBB2-negative metastatic breast cancer and active brain metastases, addressing a critical unmet clinical need.

Clinical Updates Wellness & Lifestyle

Prognostic Role of HER2 Amplification and Mutations in Metastatic Colorectal Cancer: Insights from Eight Randomized Trials

By MedXY 09/10/2025

HER2 amplification/mutation in RAS/BRAF wild-type metastatic colorectal cancer is a negative prognostic factor but does not predict differential benefit from bevacizumab or anti-EGFR therapies, based on analysis of 1,604 patients across eight randomized trials.

Clinical Updates Wellness & Lifestyle

Toripalimab Plus Bevacizumab vs Sorafenib as First-Line Therapy in Advanced Hepatocellular Carcinoma: Results from the Phase 3 HEPATORCH Trial

By MedXY 08/02/2025

The HEPATORCH phase 3 trial demonstrates that toripalimab plus bevacizumab significantly improves survival outcomes versus sorafenib in previously untreated advanced hepatocellular carcinoma, with manageable safety.

Clinical Updates

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer: New Therapeutic Prospects

By MedXY 08/01/2025

A phase 2 study shows that bevacizumab and erlotinib combination therapy offers notable tumor responses and survival benefits in both hereditary and sporadic papillary renal-cell carcinoma, with manageable toxicity.